OBJECTIVE: We sought to measure the prevalence of illicit drug use in our obstetric population, to identify the drugs being used, and to determine whether a modified version of the 4Ps Plus screening tool could serve as an initial screen. STUDY DESIGN: In this prospective study, urine samples of 200 unselected patients presenting for initiation of prenatal care in a Wisconsin private practice were analyzed for evidence of the use of illicit drugs. RESULTS: Of 200 patients, 26 (13%) had evidence of drugs of abuse in their urine samples. Marijuana (7%) and opioids (6.5%) were the most commonly identified drugs. Adding 5 questions about drug or alcohol use to the obstetric intake questionnaire proved sensitive in identifying patients with high risks of having a positive drug screen. CONCLUSION: The rate of drug use in our low-risk population was higher than expected and may reflect increasing rates of drug use across the United States. Enhanced screening should be performed to identify patients using illicit drugs in pregnancy to improve their care. Medical centers and communities may benefit from periodic testing of their community prevalence rates to aid in appropriate care planning.
OBJECTIVE: We sought to measure the prevalence of illicit drug use in our obstetric population, to identify the drugs being used, and to determine whether a modified version of the 4Ps Plus screening tool could serve as an initial screen. STUDY DESIGN: In this prospective study, urine samples of 200 unselected patients presenting for initiation of prenatal care in a Wisconsin private practice were analyzed for evidence of the use of illicit drugs. RESULTS: Of 200 patients, 26 (13%) had evidence of drugs of abuse in their urine samples. Marijuana (7%) and opioids (6.5%) were the most commonly identified drugs. Adding 5 questions about drug or alcohol use to the obstetric intake questionnaire proved sensitive in identifying patients with high risks of having a positive drug screen. CONCLUSION: The rate of drug use in our low-risk population was higher than expected and may reflect increasing rates of drug use across the United States. Enhanced screening should be performed to identify patients using illicit drugs in pregnancy to improve their care. Medical centers and communities may benefit from periodic testing of their community prevalence rates to aid in appropriate care planning.
Authors: Mahek Garg; Laura Garrison; Lawrence Leeman; Ajna Hamidovic; Matthew Borrego; William F Rayburn; Ludmila Bakhireva Journal: Matern Child Health J Date: 2016-01
Authors: Ann C Falkenberg-Olson; Karen L Hayter; Renee A Holzer; Jayne M Laylan; Andrew J Borgert; Ann E Budzak Garza Journal: Clin Med Res Date: 2020-10-14
Authors: Laura Garrison; Lawrence Leeman; Renate D Savich; Hilda Gutierrez; William F Rayburn; Ludmila N Bakhireva Journal: J Reprod Med Date: 2016 Jul-Aug Impact factor: 0.142
Authors: Elizabeth E Krans; Susan L Zickmund; Vinod K Rustgi; Seo Young Park; Shannon L Dunn; Eleanor B Schwarz Journal: Subst Abus Date: 2015-11-16 Impact factor: 3.716
Authors: David M Haas; Derek J Marsh; Danny T Dang; Corette B Parker; Deborah A Wing; Hyagriv N Simhan; William A Grobman; Brian M Mercer; Robert M Silver; Matthew K Hoffman; Samuel Parry; Jay D Iams; Steve N Caritis; Ronald J Wapner; M Sean Esplin; Michal A Elovitz; Alan M Peaceman; Judith Chung; George R Saade; Uma M Reddy Journal: Obstet Gynecol Date: 2018-05 Impact factor: 7.661
Authors: Camilla A Michalski; Rayjean J Hung; Ryan A Seeto; Cindy-Lee Dennis; Jennifer D Brooks; Joanna Henderson; Robert Levitan; Stephen J Lye; Stephen G Matthews; Julia A Knight Journal: BMC Pregnancy Childbirth Date: 2020-12-11 Impact factor: 3.007